KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Operating Expenses (2016 - 2025)

Biogen (BIIB) has 17 years of Operating Expenses data on record, last reported at $516.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.16% year-over-year to $516.0 million; the TTM value through Dec 2025 reached $3.9 billion, down 35.51%, while the annual FY2025 figure was $1.8 billion, 58.61% down from the prior year.
  • Operating Expenses reached $516.0 million in Q4 2025 per BIIB's latest filing, down from $2.0 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.7 billion in Q4 2021 and bottomed at $469.4 million in Q1 2025.
  • Average Operating Expenses over 5 years is $1.7 billion, with a median of $1.9 billion recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 134.88% in 2023, then plummeted 75.65% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $2.7 billion in 2021, then fell by 29.17% to $1.9 billion in 2022, then grew by 7.96% to $2.1 billion in 2023, then crashed by 75.65% to $510.1 million in 2024, then grew by 1.16% to $516.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $516.0 million in Q4 2025, $2.0 billion in Q3 2025, and $982.1 million in Q2 2025.